Print E-mail
Volume 38, Number 6, December 2005

Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan — a preliminary report


Tien-Chi Liang, Yao-Hsu Yang, Yu-Tsan Lin, Bor-Luen Chiang
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

Received: July 8, 2004    Revised: March 3, 2005    Accepted: May 3, 2005   

 

Corresponding author:

Bor-Luen Chiang, M.D., Ph.D, Department of Pediatrics, National Taiwan University Hospital, No 7., Chung-Shan South Road, Taipei, Taiwan. E-mail: gicmbor@ha.mc.ntu.edu.tw This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

 



 

Methods:

Tumor necrosis factor (TNF) is a major inflammatory cytokine involved in the pathogenesis of juvenile rheumatoid arthritis (JRA). Etanercept, approved in the United States and in Europe for use in patients with rheumatoid arthritis (RA) and JRA, is an effective inhibitor of TNF that has been shown to provide rapid and sustained improvement in both diseases. Here we report the preliminary results of etanercept use in 3 cases of JRA with poor response to traditional therapy including non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs. Two of the patients had polyarticular JRA and 1 had systemic JRA. Etanercept was administered at a dosage of 0.4 mg/kg (maximum 25 mg) subcutaneously twice a week. Clinical as well as inflammatory parameter improvement was noted after use of etanercept in all cases. The preliminary results of etanercept use in these 3 cases showed significant clinical benefit without obvious adverse effects.

 



 

Key words:

Etanercept, juvenile rheumatoid arthritis, tumor necrosis factor-alpha



 



 

J Microbiol Immunol Infect 2005;38:447-450.